secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001023024-25-000002
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma prelim Q4/FY24 Cortrophin Gel rev $197.8-198.4M; FY25 rev guidance $739-759M
--------------------------------------------------------------------------------

- Cortrophin Gel net rev Q4: $59.2-59.8M; FY24: $197.8-198.4M.
- ILUVIEN/YUTIQ net rev Q4: $26.6-27.2M; post-acquisition period (Sep 16-Dec 31): $30.4-31.0M.
- FY24 total rev, adjusted EBITDA, adjusted EPS expected at or above guidance issued Nov 8, 2024.
- FY25 outlook: total rev $739-759M (24-27% growth vs FY24 midpoint); adj EBITDA $182-192M.
- Full FY24 and detailed FY25 guidance to be reported in late Feb 2025 earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000002/0001023024-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000002/ani-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001023024-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer